Sandu Pharmaceuticals Ltd — Dividend/Bonus, 11-08-2026: Corp. Action

Sandu Pharmaceuticals' Board has approved its financial results for the quarter ended June 30, 2026, reporting Revenue from Operations of 16.39 Cr and a Profit for the Period of 0.23 Cr, with Basic Earnings Per Share at 0.37. The Board also approved the annual reports for the financial year ended March 31, 2026. Shareholders should note the Record Date for proposed dividend eligibility is September 4, 2026, and the 41st Annual General Meeting is scheduled for September 11, 2026. Additionally, the Board proposed member approval for continuing material related party transactions and the appointment of M/s. Dave & Dave as Statutory Auditors for a five-year term.